Source: Clinical Trials Arena

Vedanta: Vedanta Biosciences doses first subject in Phase III C. difficile prevention trial

Vedanta Biosciences dosed the first subject in the Phase III RESTORATiVE303 trial of VE303 for preventing recurrent C. difficile infection.The post Vedanta Biosciences doses first subject in Phase III C. difficile prevention trial appeared first on Clinical Trials Arena.

Read full article »
Vedanta's Competitors | Vedanta's News | Vedanta's Financials
Stay up-to-date with the latest news on Vedanta
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Bernat Olle's photo - Co-Founder & CEO of Vedanta

Co-Founder & CEO

Bernat Olle

CEO Approval Rating

84/100

Read more
Stay up-to-date with the latest news on Vedanta